Arizona Biological Research Institute

4745 North 7th Street, Suite 425

Phoenix, Arizona 85014

21 February, 2002

Summary of work by Tsuneo Kobayashi, M.D.

Dr. Kobayashi, an oncologist in Saitama, Japan has developed a panel of ten tumor markers coupled with a computerized algorithm that is useful in the early detection of cancer.

The tumor markers are categorized into three types:

                        I) Tumor Specific Markers

                        II) Tumor Associated Tumor Markers

                        III) Growth Related Tumor Markers

I) Tumor Specific Markers:

            1) CEA

            2) CHO 19-9

            3) heat-stable alkaline phosphatase

            4) tissue polypeptide antigen

II) Tumor Associated Tumor Markers:

            1) serum ferritin

            2) ferritin/serum iron ratio

            3) immunosuppressive acidic protein

            4) sialic acid

III) Growth Related Tumor Markers:

            1) alkaline phosphatase isoenzymes

            2) ribonuclease

Dr. Kobayashi has not only refined the sensitivity and range of the normal values of these markers, but has weighted there level of importance and interrelationship as a pattern recognition for 5 tumor stages.

                        I)          Tumor free

                        II)         Precancer

                        III)        Precancer

                        IV)       Preclinical cancer

V)                Suggestive of cancer weighing over 1 gram

This tumor classification can adequately assess the risk of cancer developing in apparently healthy persons.

Through interpreters, we have learned that Dr. Kobayashi has kept approximately 15,000 patients cancer and free over an 18 year duration, by implementing primarily natural methods of treatment during stages IV & V.

Dr. Kobayashi is willing to share this methodology and algorithm with us provided we adhere to his meticulous laboratory techniques.

Our initial phase will be to learn and replicate his laboratory techniques in Japan, then apply them in the United States through his interaction by split sample assays.  Once he is comfortable with our accuracy, he is willing to share his algorithm so that we may establish epidemiologic patterns within the United States.

Our secondary phase will consist of applying some of his methods in deterring cancer formation at a clinically diagnosed level as well as utilizing other natural methods known in the field of biological medicine that include, but are not limited to hyperthermia, mistletoe therapy, fasting, detoxification, nutritional and botanical therapy.

We will propose this through grant applications from our nonprofit organization, the Arizona Biologic Research Institute.

Respectively,

Frank W. George, DO, MD(H)

Medical Director, AZBRI